Pitt Street Research | Stock research

AdAlta

AdAlta is a clinical stage company with its lead candidate AD 214 developed for Idiopathic Pulmonary Fibrosis (IPF). AD 214 received FDA Orphan Drug Designation in February 2021 and completed its Phase I safety study for an intravenous formulation of AD-214 in July 2021. AdAlta has now initiated an inhaled formulation program for AD-214. AD-214 utilises AdAlta’s i-body platform, which is designed to address drug targets where traditional and much larger monoclonal antibodies have been sub-optimal.

AdAlta (ASX:1AD)

AdAlta develops antibody-like drugs called ‘i-bodies’ with the same target specificity and affinity as monoclonal antibodies, but about 90% smaller. AdAlta’s first clinical product from its platform will be indicated for the treatment of Idiopathic Pulmonary Fibrosis.